Navigation Links
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
Date:11/13/2013

DEERFIELD, Ill., Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile.

BAX 855 was designed based on the full-length ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] molecule, a product with 10 years of real-world experience. The BAX 855 molecule was modified with PEGylation technology designed to extend its duration of activity in the body.

"The BAX 855 development program is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with hemophilia," said Anders Ullman, M.D., Ph.D., vice president of global research and development in Baxter's BioScience business. "We are focused first and foremost on strategies to address optimal efficacy and minimize patients' bleeding episodes, while at the same time delivering on the convenience of less frequent dosing for this population with severe disease."

The Phase II/III multi-center, open-label study called PROLONG-ATE is evaluating BAX 855 among 146 adult patients with previously-treated severe hemophilia A. Patients participating in PROLONG-ATE receive treatment twice weekly (45 IU/kg) and are followed for six months. The primary endpoint of the study is the annualized bleed rate (ABR) during the treatment period.  The study is also evaluating the safety and immunogenicity of the compound when administered on either prophylaxis and on-demand treatment regimens. Other outcome measures include number of infusions needed t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology news :

1. NSF report detailing growth in graduate enrollment in science & engineering in the past decade
2. King Richard III search in new phase after discovery has potential to rewrite history
3. National Geographic unveils new phase of genographic project
4. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
5. In beef production, cow-calf phase contributes most greenhouse gases
6. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
7. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
8. Carnegie Mellon neuroscientists discover new phase of synaptic development
9. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
10. New sickle cell anemia therapy advances to Phase II clinical trials
11. Biozoom Enters Into Commercial Phase of Scanner Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Inc. (NASDAQ: AWRE ), a leading supplier of ... announced that Edmund C. Reiter has resigned, effective April 1, ... the board of the company citing personal reasons.   ... Counsel have been named co-CEOs and co-Presidents on an interim ...
... 2011 The Center for Engineering in Medicine (CEM) ... Hospital (MGH), a Harvard Teaching Hospital -- has announced ... in conjunction with event organizer Horizon House Ltd.  The ... School on July 14-15, and expects to draw over ...
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... bioimplants processed from human amniotic membrane, announced today the ... biologic implant specifically processed to offer a wide variety ... also announces the hiring of Frank Burrows as its ...
Cached Biology News:Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4
(Date:4/30/2015)... - Continued Advancement Toward ...   Shire (LSE: SHP, NASDAQ: SHPG ... March 31, 2015. Financial Highlights Q1 ... Total revenues $1,488 million +11% +15% Non GAAP operating ... from continuing operations $475 million +55% Non GAAP EBITDA ...
(Date:4/30/2015)... 2015 SureClinical, a leader in cloud-based ... has joined SureClinical’s executive team as Chief Financial Officer. ... technology executive with over 25 years in leadership roles ... , Ms. Morris joins SureClinical from Marrone Bio Innovations ... CFO of MBI from its founding in 2006 until ...
(Date:4/29/2015)... 29, 2015 SPIE DSS, ... on the East Coast, reaffirmed its value last week ... developers, and industry suppliers to meet and advance the ... applications. , The event included 55 conferences in two ... sensing and imaging -- and an exhibition showcasing 382 ...
(Date:4/29/2015)... CENTENNIAL, Colo. , April 29, 2015 /PRNewswire-USNewswire/ ... largest providers of cartilage, cellular, bone, skin and ... wound care to advance patient healing, announced the ... The Centers for Medicare & Medicaid Services (CMS) ... graft, from the low-cost to the high-cost category ...
Breaking Biology Technology:Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Julie I. Morris Joins SureClinical as Chief Financial Officer 2SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4AlloSource Announces New Possibilities In Wound Care 2
... Inc. (Nasdaq: MEDX ) announced today that ... be the subject of poster presentations at the Annual ... being held April 18-22, 2009 in Colorado:, ... "A Phase I, open-label, dose-escalation, multi-dose study of MDX-1401 ...
... Symbol: MSEDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced financial and operational results ... has demonstrated the ability to safely affect MS progression ... results of the Canadian/European trial (MAESTRO-01) in the second ...
... Patents in Each of the Three Critical Areas of ... Corporation, a leading developer of targeted, systemic RNA interference ... and Trademark Office (USPTO) has issued the company a ... of a potent small interfering RNA (siRNA) sequence. ...
Cached Biology Technology:Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research 2BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence 2
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
... Ventilates and removes chemical ... of exhaust. Bonded charcoal filters ... impellers ensure safe exhaust flow ... 15" access opening. Includes air ...
... benchtop ductless exhaust hood ventilates and ... indoor release of exhaust. Bonded charcoal ... 28" of vertical clearance (with access ... polypropylene spill tray; options include final ...
...
Biology Products: